Jennifer Wright

3.1k total citations · 1 hit paper
61 papers, 1.9k citations indexed

About

Jennifer Wright is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jennifer Wright has authored 61 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 17 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jennifer Wright's work include Childhood Cancer Survivors' Quality of Life (17 papers), Sarcoma Diagnosis and Treatment (16 papers) and Acute Lymphoblastic Leukemia research (12 papers). Jennifer Wright is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (17 papers), Sarcoma Diagnosis and Treatment (16 papers) and Acute Lymphoblastic Leukemia research (12 papers). Jennifer Wright collaborates with scholars based in United States, Japan and Australia. Jennifer Wright's co-authors include Anne C. Kirchhoff, Mark Fluchel, Echo L. Warner, Michael J. Heller, Sareh Manouchehri, Stuart Ibsen, Ken R. Smith, Courtney R. Lyles, Bob S. Carter and Sadik C. Esener and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jennifer Wright

58 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Wright United States	21	573	521	457	454	321	61	1.9k
Hope E. Uronis United States	24	848 1.5×	1.5k 2.9×	428 0.9×	104 0.2×	478 1.5×	119	2.3k
Leo Mascarenhas United States	28	1.3k 2.3×	966 1.9×	792 1.7×	551 1.2×	328 1.0×	149	3.1k
Helen Hickey United Kingdom	19	846 1.5×	1.9k 3.7×	302 0.7×	267 0.6×	554 1.7×	46	3.4k
Chris Holcombe United Kingdom	20	325 0.6×	526 1.0×	144 0.3×	100 0.2×	488 1.5×	81	1.8k
Cristina Meazza Italy	32	2.1k 3.7×	1.3k 2.5×	577 1.3×	465 1.0×	287 0.9×	128	3.6k
Rob C.M. Pelger Netherlands	32	679 1.2×	1.0k 2.0×	686 1.5×	121 0.3×	344 1.1×	131	3.0k
Martin G. McCabe United Kingdom	24	908 1.6×	672 1.3×	342 0.7×	343 0.8×	107 0.3×	81	2.1k
Helen Nadel Canada	26	1.0k 1.8×	404 0.8×	270 0.6×	276 0.6×	215 0.7×	102	2.5k
Peter Oppelt United States	31	479 0.8×	800 1.5×	431 0.9×	306 0.7×	236 0.7×	149	2.8k
Iyad Sultan Jordan	26	1.3k 2.2×	941 1.8×	666 1.5×	195 0.4×	169 0.5×	126	3.1k

Countries citing papers authored by Jennifer Wright

Since Specialization

Citations

This map shows the geographic impact of Jennifer Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Wright more than expected).

Fields of papers citing papers by Jennifer Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Wright. The network helps show where Jennifer Wright may publish in the future.

Co-authorship network of co-authors of Jennifer Wright

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Wright. A scholar is included among the top collaborators of Jennifer Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Wright. Jennifer Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koyama, Takahiko, Apurvasena Parikh, Rachel Galot, et al.. (2025). 1016eTiP A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress). Annals of Oncology. 36. S620–S621.

Lakhani, Nehal J., Davide Melisi, Vivek Subbiah, et al.. (2025). MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors.. Journal of Clinical Oncology. 43(4_suppl). 2 indexed citations

Liu, Jiangang, David S. Moura, Robin L. Jones, et al.. (2024). Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE. Clinical Cancer Research. 30(11). 2598–2608. 1 indexed citations

Morgenstern, Daniel A., Michela Casanova, Cornelis M. van Tilburg, et al.. (2024). Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.. Journal of Clinical Oncology. 42(16_suppl). 10022–10022. 2 indexed citations

Subbiah, Vivek, Jürgen Wolf, Bhavana Konda, et al.. (2022). Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. The Lancet Oncology. 23(10). 1261–1273. 244 indexed citations breakdown →

Mascarenhas, Leo, Chitose Ogawa, Theodore W. Laetsch, et al.. (2021). Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine. 10(3). 843–856. 2 indexed citations

Jones, Robin L., Andrew J. Wagner, Akira Kawai, et al.. (2021). Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research. 27(14). 3861–3866. 31 indexed citations

Hernando, Jorge, Mimi I. Hu, Eric J. Sherman, et al.. (2020). 1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). Annals of Oncology. 31. S1091–S1091. 3 indexed citations

Wu, Yelena P., et al.. (2020). Healthcare provider perspectives on pediatric cancer survivorship care plans: a single institution pilot study. Supportive Care in Cancer. 29(2). 697–706. 6 indexed citations

10.

Mooney, Ryan, Avery E. Holton, Katie A. Devine, et al.. (2016). Adolescent and Young Adult Cancer Survivors' Perspectives on Their Internet Use for Seeking Information on Healthy Eating and Exercise. Journal of Adolescent and Young Adult Oncology. 6(2). 367–371. 20 indexed citations

11.

Randall, R. Lor, Jennifer Wright, Holly Spraker‐Perlman, et al.. (2016). Long‐term survivors of childhood bone and soft tissue sarcomas are at risk of hospitalization. Pediatric Blood & Cancer. 64(6). 5 indexed citations

12.

Wu, Yelena P., Jaehee Yi, Tian Tian, et al.. (2015). Barriers and Facilitators of Healthy Diet and Exercise Among Adolescent and Young Adult Cancer Survivors: Implications for Behavioral Interventions. Journal of Adolescent and Young Adult Oncology. 4(4). 184–191. 49 indexed citations

13.

Nam, Gina, Sapna Kaul, Yelena P. Wu, et al.. (2015). A meta-analysis of body mass index of adolescent and adult survivors of pediatric acute lymphoblastic leukemia. Journal of Cancer Survivorship. 9(3). 412–421. 16 indexed citations

14.

Warner, Echo L., et al.. (2015). An Assessment to Inform Pediatric Cancer Provider Development and Delivery of Survivor Care Plans. Journal of Cancer Education. 30(4). 677–684. 4 indexed citations

15.

Warner, Echo L., Gina Nam, Yingying Zhang, et al.. (2015). Health behaviors, quality of life, and psychosocial health among survivors of adolescent and young adult cancers. Journal of Cancer Survivorship. 10(2). 280–290. 66 indexed citations

16.

Kirchhoff, Anne C., Holly Spraker‐Perlman, Molly McFadden, et al.. (2014). Sociodemographic Disparities in Quality of Life for Survivors of Adolescent and Young Adult Cancers in the Behavioral Risk Factor Surveillance System. Journal of Adolescent and Young Adult Oncology. 3(2). 66–74. 27 indexed citations

17.

Kirchhoff, Anne C., Roberto E. Montenegro, Echo L. Warner, et al.. (2014). Childhood cancer survivors’ primary care and follow-up experiences. Supportive Care in Cancer. 22(6). 1629–1635. 25 indexed citations

18.

Kirchhoff, Anne C., Courtney R. Lyles, Mark Fluchel, Jennifer Wright, & Wendy M. Leisenring. (2012). Limitations in health care access and utilization among long‐term survivors of adolescent and young adult cancer. Cancer. 118(23). 5964–5972. 119 indexed citations

19.

Brown, Scott A., et al.. (1996). Evaluation of a single injection method, using iohexol, for estimating glomerular filtration rate in cats and dogs. American Journal of Veterinary Research. 57(1). 105–110. 83 indexed citations

20.

Wright, Jennifer, et al.. (1982). OCULAR LEUKAEMIA IN ACUTE LYMPHOBLASTIC LEUKAEMIA OF CHILDHOOD. PubMed. 10(4). 255–262. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact